Clinical Trial Search

Primary: Injection Site Skin Reactions — 4 events

Primary: Mean Weekly Blood Glucose — 187; 178 mg/dL

Primary: Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months — -5.20; -4.83 nmol*min/L — p=0.33

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: 2 Hour C-peptide AUC in Response to MMTT — 358; 495 pmol/L — p=0.81

Primary: Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13 — 4.026; 3.886 log(ng*hr/ml [0-2 h]+1) — p=0.3303

Primary: The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit — 0.448; 0.350; 0.418 nmol/L — p=0.98

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B…

Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05

Primary: ß-cell Response Measured by Hyperglycemic Clamp — 3.65; 3.58; 3.60; 3.73 nmol/L — p=>0.05

Primary: Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) — -0.352; -0.460 percentage of glycosylated hemoglobin — p=0.055

Primary: Change in Metabolic Function Baseline to 12 Months. — 0.74; 0.43 nmol/L/min — p=0.017

Primary: Mean Fasting Blood Glucose Level — 136.4; 131.2 mg/dl

Primary: Peak Post-prandial Venous Glucose Levels — 98; 76 mg/dL — p=0.05

Primary: Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52 — -0.16…

Primary: Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline — 0.934; 0.783; 0.709; 0.660…

Primary: Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1…

Primary: HbA1c (%) — 7.92; 7.48; 7.45; 7.58 Percent of Hemoglobin (%)

Primary: Change in Hemoglobin A1c (HbA1c) — -3.18; -3.00 percentage of HbA1c

Primary: Time From Randomization to Confirmed Abnormal Glucose Tolerance Test — 89.2; 71.6 months

Primary: Change in C-peptide Measurement as Reflection of Insulin Secretion at 6 Months — -0.07; -0.07 nmol/L*120 min

Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.

Primary: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12 — -0.21; -0.21 nanomoles per…

Primary: Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12 — -0.14; -0.23 nanomoles per…

Primary: Insulin Secretion-Sensitivity Index (IS-SI) — 418.4; 333 index — p=<0.04

Primary: Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months. — 0.528; 0.646; 0.406 nmol/L

Primary: Change in Mean Weekly Glucose Concentrations — 1; -10; -10; -0.3 mg/dl

Primary: HbA1c Value After 28 Days — 7.94; 8.72 HbA1c %